Kyverna Therapeutics (KYTX) Net Cash Flow (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Net Cash Flow data on file, last reported at -$91.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 131.28% year-over-year to -$91.9 million; the trailing twelve-month figure through Mar 2026 stood at -$24.7 million (up 85.26% YoY), and the FY2025 full-year result was $27.5 million, down 55.61% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$91.9 million, down from $89.9 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $189.6 million in Q1 2024 and bottomed at -$92.7 million in Q2 2024.
• The 4-year median for Net Cash Flow is -$8.1 million (2024), against an average of -$428846.2.
• Peak annual rise in Net Cash Flow reached 9137.46% in 2024, while the deepest fall reached 779.06% in 2024.
• A 4-year view of Net Cash Flow shows it stood at $11.7 million in 2023, then tumbled by 169.3% to -$8.1 million in 2024, then soared by 1209.83% to $89.9 million in 2025, then slumped by 202.18% to -$91.9 million in 2026.
• The last three Net Cash Flow figures came in at -$91.9 million (Q1 2026), $89.9 million (Q4 2025), and -$19.3 million (Q3 2025), per Business Quant data.

Peer Comparison